SynthesisArchives of gynecology and obstetrics2025
Evolution of lymphovascular space invasion in early-stage endometrial carcinoma: stratification, quantification, and clinical implications: a systematic review.
Synthesis in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeEndometrial carcinoma (EC) represents the most prevalent malignancy of the female genital tract in the United States, with lymphovascular space invasion (LVSI) recognized as a critical prognostic factor that significantly influences disease outcomes. This review aims to elucidate the evolving understanding of LVSI in early-stage EC, highlighting its implications for stratification, quantification, and clinical management.
methodsA systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Comprehensive searches of the PubMed, Web of Science, and Embase/MEDLINE databases were performed for studies published from January 1, 1985, to November 16, 2024. Peer-reviewed articles that reported multivariable hazard ratios (HR) for LVSI in endometrial cancer were included, while meta-analyses, reviews, and case reports were excluded from analysis.
resultsA total of 6 studies involving 2,345 patients were included. The majority of the population was characterized by endometrioid histotype (85.7%) and classified as FIGO stage I (75.1%). LVSI was documented in 21.5% of cases, with 62.4% of patients receiving adjuvant treatment. The literature on LVSI was categorized into three thematic areas: stratification classifications, quantitative assessments, and guideline development, illustrating the progression from binary systems to more nuanced tiered classifications that enhance prognostic accuracy.
conclusionFoundational studies established LVSI as a significant risk factor in endometrial cancer, while subsequent research has refined its classification and quantification. However, inconsistencies in LVSI thresholds among current clinical guidelines pose challenges for standardization in practice. Addressing these discrepancies through future research, including multicenter studies and the integration of emerging technologies, is crucial for improving risk stratification and clinical management of endometrial carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.